



## **Emergent BioSolutions Delivers Approximately 1 Million Doses of BioThrax(R) Ahead of Schedule to U.S. Department of Health and Human Services for Strategic National Stockpile**

February 23, 2007

Delivery Represents Approximately \$22 Million of Revenue Generated During 1Q 2007

ROCKVILLE, Md.--(BUSINESS WIRE)--Feb. 23, 2007--Emergent BioSolutions Inc. (NYSE: EBS) announced that yesterday it delivered just under one million doses of BioThrax(R) (Anthrax Vaccine Adsorbed), the only FDA licensed anthrax vaccine, to the Department of Health and Human Services (HHS) for placement into the nation's strategic national stockpile (SNS). This delivery represents revenue of approximately \$22 million generated during 1Q 2007. These doses were provided to HHS ahead of schedule under a May 2006 modified contract that required the company to deliver five million doses to HHS before May 31, 2007. Since May 2005, the company has supplied 10 million doses of BioThrax to HHS for inclusion in the SNS.

"I am very proud of the fact that we have fulfilled, ahead of schedule, our commitment to deliver an additional 5 million doses of BioThrax to HHS for placement into the SNS," stated Fuad El-Hibri, chairman and chief executive officer of Emergent BioSolutions. "HHS has to date ordered and received from us 10 million doses of BioThrax for the SNS. Having fully satisfied our existing contractual obligations to HHS, we are now prepared to assist the agency in fulfilling its previously announced requirement for 75 million doses of anthrax vaccine."

The SNS, which is administered by the U.S. Centers for Disease Control and Prevention, is a national repository of medical assets and countermeasures designed to provide state and local public health agencies with medical supplies needed to treat those affected by terrorist attacks, natural disasters, industrial accidents and other public health emergencies, such as a flu epidemic.

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of immunobiotics, such as vaccines and therapeutics that induce or assist the body's immune system to prevent or treat disease. The company's biodefense business is focused on developing and commercializing immunobiotics for use against biological agents that are potential weapons of bioterrorism. The company's commercial business is focused on developing immunobiotics for use against infectious diseases with significant unmet or underserved medical needs. More information on the company is available at [www.emergentbiosolutions.com](http://www.emergentbiosolutions.com).

Safe Harbor Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management and any other statements containing the words "believes", "expects", "anticipates", "plans", "estimates" and similar expressions are forward-looking statements. There are a number of important factors that could cause the company's actual results to differ materially from those indicated by such forward-looking statements, including our performance under existing BioThrax(R) sales contracts with the U.S. government, including the timing of deliveries under these contracts; our ability to obtain new BioThrax sales contracts with the U.S. government; our plans for future sales of BioThrax; our plans to pursue label expansions and improvements for BioThrax; our plans to expand our manufacturing facilities and capabilities; the rate and degree of market acceptance and clinical utility of our products; our ongoing and planned development programs, preclinical studies and clinical trials; our ability to identify and acquire or in license products and product candidates that satisfy our selection criteria; the potential benefits of our existing collaboration agreements and our ability to enter into selective additional collaboration arrangements; the timing of and our ability to obtain and maintain regulatory approvals for our product candidates; our commercialization, marketing and manufacturing capabilities and strategy; our intellectual property portfolio; our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and other factors identified in the company's Registration Statement on Form S-1 and subsequent reports filed with the SEC. The company disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

CONTACT: Emergent BioSolutions Inc.  
Robert G. Burrows, 301-795-1877  
Vice President, Corporate Communications  
[burrowsr@ebsi.com](mailto:burrowsr@ebsi.com)

SOURCE: Emergent BioSolutions Inc.